nach oben

Erschienen in:

04.06.2022 | COVID-19 | Case Based Review

Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review

verfasst von: Daniel Gonzalez, Latika Gupta, Vijaya Murthy, Emilio B. Gonzalez, Katrina A. Williamson, Ashima Makol, Chou Luan Tan, Farah Nadiah Sulaiman, Nor Shuhaila Shahril, Liza Mohd Isa, Eduardo Martín-Nares, Rohit Aggarwal

Erschienen in: Rheumatology International | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Anti-MDA5 (Melanoma differentiation-associated protein 5) myositis is a rare subtype of dermatomyositis (DM) characterized by distinct ulcerative, erythematous cutaneous lesions and a high risk of rapidly progressive interstitial lung disease (RP-ILD). It has been shown that SARS-CoV-2 (COVID-19) replicates rapidly in lung and skin epithelial cells, which is sensed by the cytosolic RNA-sensor MDA5. MDA5 then triggers type 1 interferon (IFN) production, and thus downstream inflammatory mediators (EMBO J 40(15):e107826, 2021); (J Virol, 2021, https://doi.org/10.1128/JVI.00862-21); (Cell Rep 34(2):108628, 2021); (Sci Rep 11(1):13638, 2021); (Trends Microbiol 27(1):75–85, 2019). It has also been shown that MDA5 is triggered by the mRNA COVID-19 vaccine with resultant activated dendritic cells (Nat Rev Immunol 21(4):195–197, 2021). Our literature review identified one reported case of MDA5-DM from the COVID-19 vaccine (Chest J, 2021, https://doi.org/10.1016/j.chest.2021.07.646). We present six additional cases of MDA5-DM that developed shortly after the administration of different kinds of COVID-19 vaccines. A review of other similar cases of myositis developing from the COVID-19 vaccine was also done. We aim to explore and discuss the evidence around recent speculations of a possible relation of MDA5-DM to COVID-19 infection and vaccine. The importance of vaccination during a worldwide pandemic should be maintained and our findings are not intended to discourage individuals from receiving the COVID-19 vaccine.

Rebendenne A et al (2021) SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol. https://doi.org/10.1128/jvi.02415-20CrossRefPubMedPubMedCentral

Yin X et al (2021) MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 34(2):108628. https://doi.org/10.1016/j.celrep.2020.108628CrossRefPubMedPubMedCentral

Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies (in eng). Front Immunol 12:773352. https://doi.org/10.3389/fimmu.2021.773352CrossRefPubMedPubMedCentral

Wang Y, Du G, Zhang G, Matucci-Cerinic M, Furst DE (2020) Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future, (in eng). Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218594CrossRefPubMed

Wu W et al (2021) Interstitial lung disease in anti-MDA5 positive dermatomyositis (in eng). Clin Rev Allergy Immunol 60(2):293–304. https://doi.org/10.1007/s12016-020-08822-5CrossRefPubMed

Gupta R, Kumar S, Gow P, Hsien-Cheng Chang L, Yen L (2020) Anti-MDA5-associated dermatomyositis (in eng). Intern Med J 50(4):484–487. https://doi.org/10.1111/imj.14789CrossRefPubMed

Li Y et al (2020) Predictors of poor outcome of Anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis (in eng). J Immunol Res 2020:2024869. https://doi.org/10.1155/2020/2024869CrossRefPubMedPubMedCentral

Huang K et al (2019) Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review (in eng). Rheumatol Int 39(11):1971–1981. https://doi.org/10.1007/s00296-019-04398-2CrossRefPubMed

Carrasco L, Arthur A, Gaitan Rueda J, Case C (2021) A rapidly progressive and rare illness: autoantibodies against melanoma differentiation-associated protein 5 (anti-MDA5): amyopathic dermatomyositis with progressive interstitial lung disease that developed after covid-19 vaccine. Chest J. https://doi.org/10.1016/j.chest.2021.07.646CrossRef

10.

Kotsiou OS, Daniil Z, Gourgoulianis KI (2017) Pneumomediastinum in MDA5-associated clinically amyopathic dermatomyositis. Rheumatol Adv Pract 1(1):rkx003. https://doi.org/10.1093/rap/rkx003CrossRefPubMedPubMedCentral

11.

McNamara L, Brady VA (2021) Is COVID-19 the culprit? A case of anti-MDA5 antibody positivity in a rapidly progressive organizing pneumonia. In: TP31. TP031 INTERESTING CASES ASSOCIATED WITH SARS-COV-2 INFECTION, (American Thoracic Society International Conference Abstracts: American Thoracic Society, pp A2002-A2002. DOI: https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2002

12.

Saud A, Naveen R, Aggarwal R, Gupta L (2021) COVID-19 and myositis: what we know so far (in eng). Curr Rheumatol Rep 23(8):63. https://doi.org/10.1007/s11926-021-01023-9CrossRefPubMedPubMedCentral

13.

Mehta P, Machado PM, Gupta L (2021) Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry (in eng). Rheumatol Int 41(6):1021–1036. https://doi.org/10.1007/s00296-021-04819-1CrossRefPubMedPubMedCentral

14.

Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A (2020) Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. https://doi.org/10.1183/13993003.01618-2020CrossRefPubMedPubMedCentral

15.

Gokhale Y et al (2020) Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship? (in eng). J Assoc Phys India 68(11):20–24

16.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors (in eng). Rheumatol Int 31(11):1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

17.

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease (in eng). Arthritis Rheum 60(7):2193–2200. https://doi.org/10.1002/art.24621CrossRefPubMed

18.

Sakamoto N et al (2019) Clinical features of Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis (in eng). Intern Med 58(6):837–841. https://doi.org/10.2169/internalmedicine.1516-18CrossRefPubMed

19.

Tsuji H et al (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis (in eng). Arthritis Rheumatol 72(3):488–498. https://doi.org/10.1002/art.41105CrossRefPubMed

20.

So H, Wong VTL, Lao VWN, Pang HT, Yip RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis (in eng). Clin Rheumatol 37(7):1983–1989. https://doi.org/10.1007/s10067-018-4122-2CrossRefPubMed

21.

Allenbach Y et al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases (in eng). Neurology 95(1):e70–e78. https://doi.org/10.1212/WNL.0000000000009727CrossRefPubMedPubMedCentral

22.

Borio G et al (2021) Skin rash and interstitial pneumonia can be a fatal combination: a rare case of anti-melanoma differentiation-associated gene 5 (MDA5)-associated interstitial lung disease (in eng). Eur J Case Rep Intern Med 8(10):002860PubMedPubMedCentral

23.

Dunga SK, Kavadichanda C, Gupta L, Naveen R, Agarwal V, Negi VS (2021) Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study (in eng). Rheumatol Int. https://doi.org/10.1007/s00296-021-04897-1CrossRefPubMed

24.

Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R (2021) Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis (in eng). Semin Arthritis Rheum 51(1):113–120. https://doi.org/10.1016/j.semarthrit.2020.10.014CrossRefPubMed

25.

Chen L, Owens K, Murina A (2020) Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema. JAAD Case Rep 6(9):909–911. https://doi.org/10.1016/j.jdcr.2020.07.019CrossRefPubMedPubMedCentral

26.

Aoyama J et al (2019) Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respir Med Case Rep 26:193–196. https://doi.org/10.1016/j.rmcr.2019.01.012CrossRefPubMedPubMedCentral

27.

Huang L et al (2021) Association of cytomegalovirus infection with anti-MDA5 Antibody-positive dermatomyositis: a prospective cohort study (in eng). Front Med (Lausanne) 8:740154. https://doi.org/10.3389/fmed.2021.740154CrossRef

28.

Megremis S et al (2020) Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis 77(10):1383–1386. https://doi.org/10.1136/annrheumdis-2020-217522CrossRef

29.

Aschman T et al (2021) Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died (in eng). JAMA Neurol 78(8):948–960. https://doi.org/10.1001/jamaneurol.2021.2004CrossRefPubMed

30.

Cao M et al (2020) COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report (in eng). BMC Pulm Med 20(1):304. https://doi.org/10.1186/s12890-020-01335-zCrossRefPubMedPubMedCentral

31.

Wang G et al (2021) Presence of Anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study (in eng). Front Immunol 12:791348. https://doi.org/10.3389/fimmu.2021.791348CrossRefPubMedPubMedCentral

32.

Ehrenfeld M et al (2020) Covid-19 and autoimmunity (in eng). Autoimmun Rev 19(8):102597. https://doi.org/10.1016/j.autrev.2020.102597CrossRefPubMedPubMedCentral

33.

Rodríguez Y et al (2020) Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 (in eng). J Autoimmun 114:102506. https://doi.org/10.1016/j.jaut.2020.102506CrossRefPubMedPubMedCentral

34.

Liu C et al (2020) Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study. medRxiv. https://doi.org/10.1101/2020.07.29.20164780CrossRefPubMedPubMedCentral

35.

Qian J, Xu H (2021) COVID-19 disease and dermatomyositis: a mini-review (in eng). Front Immunol 12:747116. https://doi.org/10.3389/fimmu.2021.747116CrossRefPubMed

36.

Thorne LG et al (2021) SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. Embo J 40(15):e107826. https://doi.org/10.1038/s41590-021-01091-0CrossRefPubMedPubMedCentral

37.

Sampaio NG et al (2021) The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep 11(1):13638. https://doi.org/10.1038/s41598-021-92940-3CrossRefPubMedPubMedCentral

38.

Dias Junior AG, Sampaio NG, Rehwinkel J (2019) A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 27(1):75–85. https://doi.org/10.1016/j.tim.2018.08.007CrossRefPubMed

39.

Sadler AJ (2018) The role of MDA5 in the development of autoimmune disease. J Leukoc Biol 103(2):185–192. https://doi.org/10.1189/jlb.4MR0617-223RCrossRefPubMed

40.

Caso F et al (2020) Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? (in eng). Autoimmun Rev 19(5):102524. https://doi.org/10.1016/j.autrev.2020.102524CrossRefPubMedPubMedCentral

41.

Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan (in eng). Arthritis Res Ther 13(6):R214. https://doi.org/10.1186/ar3547CrossRefPubMedPubMedCentral

42.

Liu G et al (2021) ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity (in eng). Nat Microbiol 6(4):467–478. https://doi.org/10.1038/s41564-021-00884-1CrossRefPubMedPubMedCentral

43.

Fischer H, Tschachler E, Eckhart L (2020) Pangolins lack IFIH1/MDA5, a cytoplasmic RNA sensor that initiates innate immune defense upon Coronavirus infection (in eng). Front Immunol 11:939. https://doi.org/10.3389/fimmu.2020.00939CrossRefPubMedPubMedCentral

44.

Gupta P, Kharbanda R, Lawrence A, Gupta L (2021) Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic. The Egyptian Rheumatologist 43(4):271–274. https://doi.org/10.1016/j.ejr.2021.06.001CrossRef

45.

Rathore U, Haldule S, Gupta L (2021) Psoriasiform rashes as the first manifestation of anti-MDA5 associated myositis (in eng). Rheumatology (Oxford) 60(7):3483. https://doi.org/10.1093/rheumatology/keaa821CrossRef

46.

Teijaro JR, Farber DL (2021) COVID-19 vaccines: modes of immune activation and future challenges (in eng). Nat Rev Immunol 21(4):195–197. https://doi.org/10.1038/s41577-021-00526-xCrossRefPubMedPubMedCentral

47.

Talotta R (2021) Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” (in eng). Clin Immunol 224:108665. https://doi.org/10.1016/j.clim.2021.108665CrossRefPubMedPubMedCentral

48.

Vojdani A, Kharrazian D (2020) Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases (in eng). Clin Immunol 217:108480. https://doi.org/10.1016/j.clim.2020.108480CrossRefPubMedPubMedCentral

49.

Goriely S, Goldman M (2007) From tolerance to autoimmunity: is there a risk in early life vaccination? (in eng). J Comp Pathol 137(Suppl 1):S57-61. https://doi.org/10.1016/j.jcpa.2007.04.013CrossRefPubMed

50.

Lundberg IE et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups (in eng). Ann Rheum Dis 76(12):1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468CrossRefPubMed

51.

Theodorou DJ, Theodorou SJ, Axiotis A, Gianniki M, Tsifetaki N (2021) COVID-19 vaccine-related myositis (in eng). QJM 114(6):424–425. https://doi.org/10.1093/qjmed/hcab043CrossRefPubMed

52.

Ramalingam S et al (2021) COVID-19 vaccine-induced cellulitis and myositis (in eng). Cleve Clin J Med 88(12):648–650. https://doi.org/10.3949/ccjm.88a.21038CrossRefPubMed

53.

Maramattom BV, Philips G, Thomas J, Santhamma SGN (2021) Inflammatory myositis after ChAdOx1 vaccination (in eng). Lancet Rheumatol 3(11):e747–e749. https://doi.org/10.1016/S2665-9913(21)00312-XCrossRefPubMedPubMedCentral

54.

Capassoni M et al (2021) AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol 93(10):5718–5720. https://doi.org/10.1002/jmv.27175CrossRefPubMedPubMedCentral

55.

Kaulen LD et al (2021) Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series (in eng). Eur J Neurol. https://doi.org/10.1111/ene.15147CrossRefPubMedPubMedCentral

56.

Gupta K, Sharma GS, Kumar A (2021) COVID-19 vaccination-associated anti-Jo-1 syndrome (in eng). Reumatologia 59(6):420–422. https://doi.org/10.5114/reum.2021.111836CrossRefPubMedPubMedCentral

57.

McHugh NJ, Tansley SL (2018) Autoantibodies in myositis (in eng). Nat Rev Rheumatol 14(5):290–302. https://doi.org/10.1038/nrrheum.2018.56CrossRefPubMed

58.

Duchesne M et al (2020) Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis (in eng). Brain Pathol 30(5):867–876. https://doi.org/10.1111/bpa.12844CrossRefPubMedPubMedCentral

59.

Milisenda JC, Doti PI, Prieto-González S, Grau JM (2014) Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature (in eng). Semin Arthritis Rheum 44(2):228–233. https://doi.org/10.1016/j.semarthrit.2014.04.004CrossRefPubMed

60.

Zheng YM et al (2020) Correlation study on anti-Ro52 antibodies frequently co-occur with other myositis-specific and myositis-associated autoantibodies (in chi). Beijing Da Xue Xue Bao Yi Xue Ban 52(6):1088–1092. https://doi.org/10.19723/j.issn.1671-167X.2020.06.016CrossRefPubMed

Titel: Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review
verfasst von: Daniel Gonzalez
Latika Gupta
Vijaya Murthy
Emilio B. Gonzalez
Katrina A. Williamson
Ashima Makol
Chou Luan Tan
Farah Nadiah Sulaiman
Nor Shuhaila Shahril
Liza Mohd Isa
Eduardo Martín-Nares
Rohit Aggarwal
Publikationsdatum: 04.06.2022
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: Rheumatology International / Ausgabe 9/2022
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-022-05149-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device

Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis

Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A case–control study using data from the UK Biobank

Age-related immunosenescence in Behçet’s disease

Assessment of TNF-α expression in unstable atherosclerotic plaques, serum IL-6 and TNF-α levels in patients with acute coronary syndrome and rheumatoid arthritis